Biotechnology
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...
2023-08-16 05:00
3859
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first
of several collaborative efforts inNorth Asia.
SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-08-16 01:00
2969
Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a glob...
2023-08-15 22:50
2996
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
NEW YORK, Aug. 15, 2023 /PRNewswire/ -- OnCusp Therapeutics, a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, announced today the clearance of its Investigational New Drug (IND) Applicatio...
2023-08-15 20:00
1587
Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Government of Hong Kong Specia...
2023-08-15 16:52
2760
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials
WUHAN, China and SAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth"), aChina's leading gene therapy company for ophthalmic diseases, announced the closing of nearly95 million USD in Series C+ financing. The round was co-led by Yangtze River-CMB International Indust...
2023-08-11 21:00
3564
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...
2023-08-11 17:00
4522
WuXi XDC and Boostimmune Sign MOU for Integrated Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating ...
2023-08-11 08:30
2205
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune micr...
2023-08-11 08:30
5215
Datasea Launches Innovative "Intelligent Acoustics" Subsidiary in Delaware, Unveiling AI-Integrated Offerings for US Market
BEIJING, Aug. 10, 2023 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology corporation engaged in three converging and innovative business segments inChina: intelligent acoustics, 5G messaging, and smart city technology, announced the inception of a who...
2023-08-10 21:30
4613
HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics
CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precisi...
2023-08-10 21:30
2972
Standigm and Nashville Biosciences join to revolutionize early drug discovery
Companies will identify novel therapeutic targets using Standigm's explainable
AI and Nashville Biosciences' datasets
SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm
2023-08-10 21:07
2597
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed...
2023-08-10 21:00
3207
Baird Medical Submits Disposable Microwave Ablation Needle and MWA System Application to U.S. FDA for Treatment of Soft Tissue Microwave Ablation
GUANGZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, today announced the 510(k) premarket notification submission of the Company's Disposabl...
2023-08-10 19:00
2257
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updat...
2023-08-08 20:00
2206
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...
2023-08-08 16:10
3416
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
* Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed, Pivotal Life Sciences, RA Capital Management and TCGX * $100 million financing upfront wi...
2023-08-07 23:14
4113
AI-based wastewater sampling predicts COVID pressure on hospitals
SYDNEY, Aug. 7, 2023 /PRNewswire/ -- New research shows it is possible to
accurately predict hospital admission numbers due to COVID-19 up to four weeks
in advance with an Artificial Intelligence (AI) based system using COVID
wastewater sampling.
2023-08-07 21:13
2442
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
BEIJING, SHANGHAI and BOSTON, Aug. 7, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that Jacobio's in-house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug ...
2023-08-07 20:03
2879
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors
SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate ("ADC") therapeutics to treat patients with cancer and autoimmune diseases, today announ...
2023-08-07 18:00
2123
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 316 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 284 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
9568
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8345
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
8289
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026-06-05 22:00
7917
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
2026-06-05 21:13
7674
